Revive Therapeutics, UCSF partner to study Bucillamine for severe Covid-19

Revive Therapeutics, UCSF partner to study Bucillamine for severe Covid-19

Submitted by admin on May 4, 2021 - 10:34am
Source: 
Pharmaceutical Business Review
News Tags: 
Revive Therapeutics
COVID-19
Bucillamine
Headline: 
Revive Therapeutics, UCSF partner to study Bucillamine for severe Covid-19
snippet: 

Specialty life sciences company Revive Therapeutics has signed a research agreement with University of California, San Francisco (UCSF) to study Bucillamine as a potential treatment for severe Covid-19.

Do Not Allow Advertisers to Use My Personal information